Introduction {#s1}
============

The dopaminergic system undergoes a delayed maturation in the brain, suggesting important stabilizing and integrating functions on neural circuits ([@B73]; [@B142]). Schizophrenia (SCZ) is associated with dopamine (DA) neurotransmission alterations during puberty and adult life causing deficits in motivation, cognition and sensory functions ([@B180]; Abi-Dargham, 2018; [@B72]; [@B185]). DA release measures in SCZ clinical studies and in preclinical models have clearly documented a fronto-cortical DA hypoactivity and a striatal (mainly dorsal) DA hyperactivity, associated with the occurrence of different SCZ symptoms ([@B194]; [@B128]; [@B162]; [@B116]). A summary of the most recent experimental evidence linking SCZ to DA alterations can be found in [**Table 1**](#T1){ref-type="table"} ([@B129]). Recent studies are however questioning the causal role of DA in SCZ in favor of a more "NMDA hypofunction hypothesis" of the disease. The limited SCZ genetic links to dopamine receptors (DR) and the main glutamatergic alterations observed in SCZ imaging studies are among the most compelling reasons for this debate ([@B48]; [@B129]) (see also supplementary material [**Table 1**](#T1){ref-type="table"} for genetic links). This clearly does not question the well documented therapeutic benefit of DR antagonists as antipsychotics, but challenges two decades of efforts to develop new and improved SCZ therapies. This review aims at providing a summary of the most recent advances in DR control in SCZ with focus on DR---glutamate NMDA interactions across the genetic, intracellula,r and synaptic aspects of the disease. ([@B161]).

###### 

Summary of most recent evidence of dopaminergic alterations in schizophrenia.
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Section 1: Dopamine Receptors {#s2}
=============================

DA Neurophysiology {#s2_1}
------------------

DA is a neurotransmitter produced in neuronal terminals by successive hydroxylation and decarboxylation of tyrosine and loaded into synaptic vesicles by the monoamine transporter 2 (VMAT2/SCL18A2). When glutamate is coreleased with DA, VGLUT2-mediated glutamate uptake causes vesicular acidification and increases DA packing ([@B57]). Released DA is targeted for reuptake by two solute carriers, DAT1/SLC6A3 and DAT/SLCA2, with a prevalence of the effect of DAT1. The degradation of DA is under the control of a methylation enzyme, COMT (highly expressed in prefrontal cortex) and presynaptic monoamine oxidases. The by-product of this oxidation, H~2~O~2~ is funneled into the mitochondrial transport chain to support further DA release ([@B37]). DA release occurs in a rather diffuse manner and ultrastructural studies show DA neuron axonal arborization and intricate projections covering large areas. DA transmission is tightly controlled at presynaptic level, while only varicosity elements define the postsynaptic sites with a variety of inputs (cholinergic, glutamatergic) in close proximity. DA neurons are specialized to receive high volumes of afferent signals and transform this information into a modulatory tone through a large projection area. It is estimated that one DA neuron provides input to several thousand neurons in the striatum and vice-versa, any given individual striatal neuron is influenced by DA released from more than one hundred DA projections. The DA neuronal system is often described in terms of DA release (tonic or phasic) and several models have tried to explain how multiple functions can be effectively impacted by different temporal DA release patterns ([@B59]; [@B15]; [@B119]; [@B133]). DA neurons are intrinsic pacemakers, with a slow (2--4 Hz) rhythmic activity associated with a tonic feed-forward control on DA receptor activation. The ionic channels/voltage sensitive mechanisms controlling DA tonic firing activity can differ even in within each DA nucleus. DA neurons can also fire in rapid bursts in response to relevant (salient) stimuli. This transient increase in firing rate induces a temporally precise rise in DA concentrations that can be synchronized in within local circuits. The lack of canonical synaptic release sites and the low probability of release for DA containing vesicles allow a scaling of neurotransmitter release as a function firing frequencies ([@B113]). DA neurons in normal conditions always contain a "reserve pool" of DA vesicles that are rather insensitive to stimulation and more than half of DA synaptic release sites are functionally silent when stimulated. The DA system is therefore also sensitive to a local presynaptic modulation from other neurotransmitters (like acetylcholine or endocannabinoids) ([@B227]). DAT exerts a main presynaptic master control on DA release as recently demonstrated ([@B45]; [@B208]). DA release is in fact directly modulated at the presynaptic terminals by a Rho-dependent internalization of DAT. This prolongs DA availability after burst stimulation, causing a prolonged postburst increase (\>20 min) ([@B118]). Differences in presynaptic Ca^2+^ channels and Ca^2+^ buffering further contribute to DA release synaptic heterogeneity ([@B40]). Large postexperience DA stimulation phases are important during learning procedures and in motivational drive, reward processes ([@B111]; [@B184]). Most likely both D1 and D2 receptors subtypes are differentially engaged when in presence of DA burst firing at least in cortical and striatal regions ([@B90]). Experimental evidence points at presynaptic alterations in DA nerve terminals in the striatal region and in prefrontal cortex in SCZ ([@B40]; [@B129]; [@B217]). Independent groups have reported alterations in the DAT level or function in SCZ patients ([@B10]; [@B198]; [@B120]; [@B174]), but some of the results are still contradictory ([@B67]). The described SCZ increase in DA synthesis/release in the rat dorsal striatum can be reproduced in preclinical models with alterations which resemble SCZ early symptoms ([@B153]). These general features are confirmed in a mouse model of NMDA receptor hypofunction in GABAergic neurons during development ([@B139]), in mouse models studying SCZ genetic links to CACNA1C ([@B194]) and in Neuregulin 2 KO mice ([@B230]). Recent data managed to shed further light on the synaptic proteins involved in DA release, and how these are linked to SCZ by genetic studies. For instance both the somato-dendritic and axonal release of DA are controlled by RIM protein isoforms in the active zone and by the Rab3 counterpart *via* D2L receptors ([@B166]). Glutamatergic effects on the DA release machinery are most likely indirect and sustained by GABAergic interneurons at least in cortical regions ([@B134]). In fact, antipsychotic agents do not completely manage DA synthesis/release alterations, even in presence of efficacy on psychotic symptoms ([@B221]; [@B219]).

DR Subtypes {#s2_2}
-----------

DR are integral membrane receptors coupled to G proteins ([@B14]; [@B195]). The dopaminergic system signals through "D1-like" D1 and D5 receptor subtypes and "D2-like": D2Short (S), D2Long (L), D3 and D4 receptor subtypes ([@B226]). There is some difference in the affinity of DA for D1-like receptors and D2-like receptors, mostly reported on the basis of receptor-ligand binding studies in recombinant systems ([**Supplementary Material: Table 1**](#SM1){ref-type="supplementary-material"}). D2-like receptors have a 10- to 100-fold greater affinity for DA than the D1-like family, suggesting that the balance of D2-like vs. D1-like receptor signaling can change depending on extracellular DA concentrations. A general view supports the specific engagement of D1 receptors in cortical regions when in presence of burst firing ([@B55]; [@B137]) while DA tonic activity affects only postsynaptic D2-like receptor signaling ([@B32]). Differences in DR affinity may not be however the only relevant factor when discussing DR engagement in physiological conditions. The timescale of DR engagement (minutes) and the relative DR abundance in complex circuits need to also be taken into account ([@B90]). The role of DR in different neuronal populations in striatum can be an example of this complexity. D1 and D2 receptors are generally segregated in striatal GABAergic medium spiny neurons (MSNs). D1-MSNs respond mostly to DA burst signals ([@B232]), while optogenetic studies show that the effect of DA burst firing on D2 is not occluded by the presence of a background DA tone. D2-MSNs can therefore respond to a broader range of stimuli ([@B125]). Cholinergic interneurons in the same region also receive an important DA/glutamate corelease input during burst firing. These cholinergic neurons express the receptor D5 (D1-like) responsible for an excitatory response after a bursts of DA release and D2-like receptors which trigger an hyperpolarization (a pause in the cholinergic signaling sequence) when activated. These events are in temporal sequence with the NMDA activation after glutamate/DA corelease creating a specific pattern of activity in these interneurons ([@B222]). In the nucleus accumbens (nAcc) finally D1 and D2-like receptors work in cooperativity (heterodimers) in the same neuronal population and still a local complex coding of response to DA release fluctuations can support motivation and decisional processes ([@B81]).

The original classification of DRs subtypes signaling mechanisms on the basis of cAMP stimulation and/or inhibition is no longer so useful given the substantial complexity of the heterocomplexes formed by DR. The DR - cAMP cascade is in any case directly linked to mRNA translation enhancement *via* PKA and serine-residues phosphorylation of ribosomal protein S6. So transcriptional - translational control can be considered a specific part of the DRs activation cascade. Only D1 and D2/D3 will be further discussed in this review as DR most involved in SCZ related alterations. D5 research did not produce convincing evidence so far of robust SCZ association ([@B92]) and a link to stress and GABA transmission is the only new element of relevance for D4 in SCZ psychosis ([@B192]).

D1 Receptors {#s2_3}
------------

When discussing D1 in the context of SCZ, the most important aspects are certainly related to the prefrontal cortex (PFCx) regions and the cognitive deficits observed during the disease ([@B9]). D1 activates a postsynaptic Gs/Golf protein complex with a final increase in intracellular cAMP levels. PDE1b is the most relevant enzyme for the cAMP degradation upon D1 activation ([@B229]; [@B231]). Two cAMP sensors link D1 activation to the ERK cascade: PKA and NCS-RAP/GEF2. Both proteins are important to trigger neuroplasticity effects ([@B98]). Prolonged agonist activation of the D1 receptor leads to phosphorylation of the intracellular domains by G protein coupled receptor (GPCR) serine and threonine kinases (GRKs) and other kinases like GSK3b. They trigger the translocation and coupling of β-arrestins and D1 receptor endocytosis ([@B213]). The scaffolding function of β-arrestins enables the gathering of various other signaling components (cAMP independent). D1/D3 heterocomplexes transactivation can also switch D1 signal toward a cAMP independent cascade ([@B77]). D1 has been the focus of past SCZ research because of its functional role in the potentiation of postsynaptic NMDA currents *via* a receptor complex with NR1a/NR2a including PSD95 ([@B234]; [@B54]). D1 activation triggers NR1-CaMKII coupling and enhancement of CaMKII activity; mGlu5 phosphorylation by MAPK and potentiation of the effect of Pin1 - Homer1 ([@B136]). A multicompartment model of this control in striatal medium spiny neurons (MSN) involves STEP tyrosine phosphatase ([@B16]; [@B79]). The D1-dependent engagement of Fyn kinase leads to an enhancement of NMDA NR2b subunit channel activity also of specific relevance in MSN in striatum ([@B86]) NMDA -- D1 interplay *via* Fyn kinase could be also more broadly relevant across glutamatergic synapsis in cortical regions given the long term effect on the function of ELF2 ([@B51]). A more downstream control on the same path can be made *via* PKA activation and by PDE10 inhibitors and similar considerations can be applied to D2 intracellular cascade in MSN ([@B141]; [@B83]). D1 may be present in heterologous glutamatergic pre-synapsis possibly in heterocomplexes (D3)? in prefrontal cortex and hippocampus with an effect on glutamate release ([@B85]).

D2/D3 Receptors {#s2_4}
---------------

D2-like receptors (D2/D3) are the main targets of antipsychotics ([@B237]). The D2 receptor is present in two isoforms D2S and D2L which differ because of a 29 AA insertion in the third intracellular loop on D2L ([@B245]). Both receptors can inhibit intracellular cAMP *via* Gi. The inhibitory effect of D2 (and D3) on membrane excitability is generally due to the coupling to GIRK channels *via* Go (Kv 1.1, 1.2, or 1.6 - possibly Kv3) ([@B87]; [@B19]). Both D2S/L receptors can initiate a cAMP-independent pathway by promoting the association of a signaling complex containing AKT1, PP2A, and β-arrestins leading to the activation of both ERK1/2 and GSK3b signals ([@B38]). The D2 receptor establishes a complex with DISC-1 that facilitates GSK3 mediated signaling and inhibits D2 agonist mediated receptor internalization, further enhancing the final D2 mediated effects ([@B187]). Antipsychotics seem to be able to uncouple this complex ([@B242]). The D2S is dominant in the cell bodies and projection axons of the dopaminergic cells in mesencephalon, while the D2L is a mainly postsynaptic receptor strongly expressed by neurons in the striatum and nAcc, brain structures targeted by DA terminals. In cell types of relevance for SCZ like MSN or cortical pyramidal neurons, D2L is able to trigger PKA activation possibly because of receptor transactivation ([@B34]). DARPP32, RCS, and ARPP16 are the most important PKA targets of the D2 effects ([@B207]). D2L activation can also recruit c-Src to transactivate the PDGF receptor and downstream Ras/Raf/MEK/ERK signaling cascade. This pathway represents a main stimulus for dendritic formation in striato-pallidal MSN ([@B177]). D2S auto-receptors (on dendrites and soma) are known to inhibits cell firing, activate DA reuptake and inhibit DA synthesis. The work of Purves-Tyson confirms that D2S, VMAT2, and DAT mRNAs are significantly decreased in schizophrenia, with no change in *DRD3* mRNAs, and DAT protein between groups ([@B157]). Other studies have verified that these alterations are sensitive to stress ([@B173]) and present in drug-naïve SCZ patients not previously treated with antipsychotics ([@B199]). In the same presynaptic compartment D2S can inhibit the trace amine receptor TAAR1 with a final potentiating effect on the DA release in striatum ([@B115]; [@B187]). The distribution of TAAR1 is predominantly intracellular thus being uniquely positioned to regulate aminergic activity (possibly including DAT function) ([@B11]). The recent positive clinical results obtained with the TAAR1 agonist SEP-363856 tested as antipsychotic provide a confirmation of the relevance of the observed alterations in presynaptic DA release in SCZ ([@B149]; [@B106]).

The D3 receptor is efficiently coupled to Gi/o at pre- and postsynaptic sites and in cell bodies. Some D3 intracellular pathways are similar to those observed for D2 ([@B77]). The D3 receptor can however be sequestered in an inactive state at the membrane level rather than internalized ([@B235]; [@B236]; [@B240]). D3 can work in complex with D1 receptor and thanks to this, D3 agonists can stimulate cAMP production and even GABA release. This D1/D3 interaction also facilitates non cAMP related intracellular signaling as demonstrated with biased ligands ([@B77]) (see section 3). At postsynaptic level in MSN, D3 modulates Ca^2+^ channels *via* PLC and PP2B. At extra-synaptic location (cell bodies) D3 receptors have been reported to selectively modulate Ca^2+^ influx through low-voltage activated (Ca~V~3, T-type) Ca^2+^ channels, in a β-arrestin-dependent mechanism. In other cases, non-canonical DR mediated events like the D3 interaction with the ghrelin receptor need to be invoked (in hippocampus) to explain a final effect *via* Galphaq-PLC-IP3-Ca^2+^ ([@B102]). The D3 receptor is able to interact with nicotinic receptors (for instance alpha 4 containing nicotinic receptors) in particular in VTA ([@B20]) and represents a main point of cross talk with the cholinergic system ([@B127]). D3 turnover is controlled by the EGFR tyrosine kinase signaling cascade ([@B238]). EGFR phosphorylates GRK2 which then phosphorylates the intracellular domain of the D3 receptor to trigger D3 intracellular receptor degradation ([@B190]). PICK1 instead seems to be able to control surface D3 levels. PICK1 is present in dopaminergic neurons in close proximity with D3 (also D2 and DAT) at cytosolic level and an increase in PICK1 lowers the surface density of D3 ([@B241]). D3 effects can be increased in presence of NMDA receptor hypofunction. Upon NMDA activation CaMKII alpha is recruited to D3 by rising Ca^2+^ to increase the CaMKII alpha-mediated phosphorylation of D3, thereby transiently inhibiting D3 efficacy ([@B117]). This CAMKII control on DA/NMDA interplay is potentially very relevant in SCZ and core to the therapeutic interventions required to limit D3 overactivation. See [**Figure 1**](#f1){ref-type="fig"} for DR and signal transduction at synaptic level.

![Simplified sketch of the dopamine receptors (DR) connectome in the basal ganglia/striatum with a zoom (right circle) on signal transduction at presynaptic level in medium spiny neurons (MSN) dendritic boutons. Highlights on the elements associated with SCZ alterations are depicted in red. D1 positive medium spiny neurons of the direct pathway (MSNd) are in green, inhibitory D2 positive MSN of the indirect pathway (MSNi) are in red. Glutamatergic cortical input - presynaptic terminals are in magenta. DA "en passant" boutons are indicated in orange and in close proximity of glutamatergic postsynaptic spines. Cholinergic interneurons are in yellow. In the magnification on the right note the distribution of DR: D2s and D3 are presynaptic in DA terminals; D1/D3 postsynaptic in MSNd and D2L postsynaptic in MSNi. Other projections are in gray. Abbreviations: ACh, acetylcholine; DA, dopamine; Glu, glutamate; MSNd/i, direct/ indirect path projecting MSN neurons; GPi, internal segment of globus pallidus; SNr, substantia nigra, reticular part; STh, subthalamic nucleus; other common abbreviation and protein names as cited in text.](fphar-11-01003-g001){#f1}

DR Dimerization and Complexes {#s2_5}
-----------------------------

As for many GPCRs, all DR subtypes form homo and heterodimers *in vivo* with effects on native receptors signaling. DR dimerization involves transmembrane domains 5 and 6. This interaction can be a transient process, stabilized in presence of agonists like dopamine or quinpirole ([@B101]) and it is of potential pathophysiological significance for SCZ. The balance of D2 homodimers to monomers has been also associated to amphetamine sensitization in animals, a further element related to SCZ ([@B217]). This is why the generation of bivalent DR ligands has been attempted by several groups ([@B33]). The most common DR heterodimers/tetramers observed *in vivo* are D1/D2, D1/D3, D1/H3 and D2/A2A ([@B21]). They all affect the MAPK response of these receptor systems, D1/D3 also modify recruitment of β-Arrestin-1 and heterodimer internalization. mGlu5/D2, D2/mu opioid receptor, D2/neurotensin 1 receptor, and D2/5-HT1a heterodimers have been also described, but not necessarily in the context of SCZ ([@B121]; [@B158]; [@B159]). They can all be potentially relevant for the effects of antipsychotic agents and for the generation of new ligands with unique pharmacological properties ([@B89]). A different type of interaction has been described for D1 and NMDA receptors. In this case the presence of a membrane cluster in hippocampal neurons has been convincingly demonstrated during the past decade ([@B110]). D1 activation is associated with increased NMDA trafficking to the synaptic surface and vice-versa. The proposed model shows D1 receptors dynamically retained in clusters in the vicinity of glutamate synapses where they interact with NMDAR. DR activation disrupts this interaction and favors the lateral redistribution of both receptors. D1Rs moves to extra-synaptic areas, whereas NMDA receptor reaches the glutamatergic postsynaptic density. Most importantly anti-NMDA antibodies from SCZ patients disrupt NMDA trafficking and reduce D1 trafficking as well. A region contained in the intracellular C-terminus of the D1 receptor is involved in this interaction with the NMDA receptor ([@B75]). More complex structures are also reported in the cortex involving D1, H3 and NMDA receptors ([@B168]).

DR Turnover {#s2_6}
-----------

Palmitoylation at the C-terminus of the DR protein has been documented for D1, D2, and D3 receptors as reversible switch for DR signaling *via* the cAMP path ([@B56]; [@B7]). The most important posttranscriptional modification of D2 and D3 receptors is the N-linked glycosylation that classically affects both correct cell surface expression and signaling/internalization (caveolin - chlatrin mediated) ([@B131]). D1 and D2 are localized to different endocytic vesicles after internalization. D1 is recycled back to the cell surface in a process controlled by the VPS35 complex ([@B212]), while prolonged agonist stimulation causes D2 trafficking into lysosomes and subsequent receptor degradation by a Rab5 GTPase controlled pathway ([@B177]; [@B178]). A specific presynaptic control on D2S membrane density is exerted by the L1 close homolog adhesion factor (also a risk gene for SCZ) ([@B109]). Presynaptic D2S receptor density is directly or indirectly affected by ALK and possible transactivation mechanisms ([@B84]). The overall complexity of the control of D2 receptor internalization (vs D3) is possibly justified by the major biological role of D2 surface density adjustments, required in different circuits depending on DA content. A specific example is the D2 vs D3 relative control by Dysbindin 1 ([@B114]). Dysbindin (SCZ risk gene associated with cognitive symptoms) is mainly expressed in hippocampus and dorsolateral (DL) PFCx. It is a component of the multi-subunit complex BLOC-1 where it interacts directly with MUTED (also probably associated with SCZ). Both dysbindin and MUTED siRNAs increase cell surface D2 receptors and block DA-induced D2 internalization in human and rat cells. Dysbindin variants are known to modify the cognitive response to antipsychotics. This effect is most likely related to the parallel Dys1/D3 signal reduction that favors a D2 component in cortical regions ([@B114]).

Other types of control on DR density are exerted at source at the transcriptional level. A recent analysis of proteasome alterations in SCZ points at spliceosome nuclear protein and calmodulin related pathways. The control on the splice variants of the D2 receptor is exerted by NOVA1 and HNRP ([@B131]), and D2 mRNA 3´UTR binding of microRNAs mir-9 and mir 328 inhibits messenger translation ([@B176]). Development mechanisms are directly impacting on DR expression. In particular DISC-1 can translocate with KLF16 into the nucleus and recruit SIN3A corepressor to the D1 locus ([@B188]). The DISC-1 related complex is a main hub that could bring more specific information on SCZ developmental aspects in terms of consecutive development related alterations in glutamatergic (NMDA/AMPA) and dopaminergic responses (D1+D2+D3) in key SCZ regions like dorso-lateral PFCx and the striatum ([@B144]; [@B95]). The expression control can also be exerted more dynamically on the D1 intracellular signal transducers by nuclear receptors like Nr4A1 (Nurr77) ([@B43]). Another nuclear factor involved in shaping dopaminergic terminals is Nurr1, highly relevant for the D2 receptor network and its circadian cycling ([@B41]; [@B197]). See [**Table 1**](#T1){ref-type="table"} supplementary material for a summary. Until puberty, the DA system maturation is controlled by the netrin-receptor DCC mediated organization of DA neurons in the meso-cortical limbic system and the projections to PFCx ([@B205]). Axon navigation is directed by extracellular axon guidance cues, which induce molecular changes in the axonal growth cones in response to extracellular levels of DA (via D1 in complex). The DCC gene keeps being a confirmed SCZ genetic link across several studies ([@B205]) with a particular effect on the anatomical connectivity of the nigra/VTA dopaminergic pathways and the final distribution and relative density of DR. In animal models, SCZ-like symptoms seem to correlate with netrin 1 - DCC related alterations in size, complexity and density of DA spines (medial PFCx layer V pyramidal neurons). Other genetic SCZ links (for example RGS12) concur on DA synthesis and release ([@B76]; [@B108]). A common upstream element affecting the expression of D2, COMT and structural proteins at presynaptic DA level is the zinc finger element ZFN804A ([@B69]), coded by another SCZ risk gene ([@B243]).

Section 2: DR Alterations in Schizophrenia {#s3}
==========================================

The current understanding of the role of DR in SCZ is in full expansion, thanks to developmental brain studies and the advancements of imaging techniques. DR expression is segregated across neuronal populations and associated with temporal and coupling differences in activation properties. This distribution is respected in SCZ, while a variety of DR β-arrestin mediated intracellular signaling show clear alterations in SCZ disease models. Some developmental and connectivity aspects of DR distribution are maintained across species and useful for the definition of SCZ as a developmental disease across circuits ([@B185]).

Prefrontal Cortex Neurocircuit(s) Affected by SCZ and DR {#s3_1}
--------------------------------------------------------

Connectivity measures across different SCZ studies are not always easy to compare, but some key elements are constant across patient groups, detection modalities and data interpretation: the involvement of striatal-thalamic and PFCx connections in SCZ ([@B239]). Imaging, functional and circadian studies are also in general agreement on the presence of main alterations in the PFCx of SCZ patients, in particular dorso-lateral and cingulate regions ([@B175]). PFCx circuits are central to cognitive functions and linked to the different aspects of cognitive deficits and positive symptoms as observed in SCZ. Dorso-lateral PFCx weaker processing of sensory information from thalamus is in fact associated with hallucination experiences which are common in \> 50% of the SCZ patients ([@B50]). The molecular studies point at parvalbumin positive (PV+) GABAergic interneurons and cortical pyramidal cells networks as both altered in SCZ PFCx and across species in SCZ models ([@B42]; [@B152]; [@B216]; [@B217]). Dopaminergic ascending terminals reaching these neurons are also hypofunctional ([@B162]). Dopamine release enables the PFCx to compute and generate spatio-temporally diverse and specialized outputs, but these are not a linear function of the DA release input. Thus, it is quite complex to establish the functional correlates for cortical functions. Rapid, transient changes in DA transmission in PFCx are observed in response to task events, such as cues and rewards whereas prolonged responses are relevant to emotional states and motivation ([@B119]). DA neurons in the region are mainly coming from the VTA and the terminal density in PFCx is much lower (in terms of DAT content) when compared to the striatal regions.

D1 receptors are enriched in pyramidal cells in both layers 5 (thin-tufted layer) and 6 projecting in turn to contralateral cortex, striatum, and claustrum. D1 receptors are also present in interneurons and enriched in a specific population of VIP+ calretinin positive interneurons ([@B6]; [@B170]). D1 receptors strongly enhance action potential firing in this subset of cortico-cortical neurons and VIP+ interneurons and the modulation *via* D1 receptors can influence both excitatory and disinhibitory microcircuits in the PFCx ([@B6]). This PV+ interneuron circuits are a the main point of interaction between mGlu5/NMDA and D1 (D2-like) receptors, both involved in the control of the glutamatergic input from pyramidal cells ([@B140]). D1 is important for the correct migration of the dopaminergic terminals which increase throughout adolescence across species. Developmental studies in netrin-1 receptor DCC deficient mice demonstrate a role for DA in adolescent brain axon growth. DCC controls in fact the extent of this protracted growth by determining where and when DA acts. Pyramidal neuron morphology studies and cognitive performances show that the lack of DCC causes dopaminergic deficit across PFCx and morphological changes in pyramidal neurons ([@B164]). This process can be influenced by stress. The DA deficit in PFCx regions following this hypothesis may be then of developmental origin and caused by morphological alterations affecting DA terminals, pyramidal cells and interneurons.

D2/3 receptors are also differentially expressed in PFCx and their activation contribute to specific cognitive processes ([@B165]; [@B13]; [@B146]). D2 are enriched within subcortically projecting L5 pyramidal neurons thick-tufted pyramidal cells, with projections to thalamus and pons, but not contralateral cortex ([@B233]). These neurons exhibit a prominent hyperpolarization-activated cationic current. In this population, pharmacological activation of D2 elicits a profound after depolarization that only occurs when NMDA receptors are coactivated. D2 signal in this case is triggering a Gs- cAMP/PKA pathway in a non-canonic manner ([@B165]). D2 are also expressed in PV+ interneurons, a property acquired during adolescent brain maturation ([@B202]). The D2 network controls the connection to the hippocampal system ([@B196]; [@B104]). Species related differences in this circuitry could be large, so human data are needed for the correct interpretation of the results ([@B71]). The cortical D2 mediated effects of the most common antipsychotics (antagonists and partial agonists) have been extensively evaluated. This is mostly because these agents cannot rescue the cognitive impairment associated with schizophrenia, with possibly few exceptions (amisulpride or 5-HT1A partial agonists) ([@B148]; [@B88]).

D3 are expressed by a distinct population of prefrontal neurons and they also represent the main auto-receptor controlling DA release in prefrontal cortex. D3 expression defines an additional class of L5 pyramidal cells that largely lack D1 or D2 coexpression. L5 D3-expressing neurons are similar to D1-expressing cells in their synaptic connectivity, with projections to contralateral cortex. D3-expressing neurons could be distinguished from D1- or D2-expressing neurons by dendritic morphology, intrinsic electro-physiological properties and by the manner in which DA regulates neuronal function. In these neurons in fact D3 selectively regulates the dynamics of voltage-gated calcium channels localized to the site of action potential initiation in the axon initial segment, with a marked suppression in the generation of high-frequency action potential bursts. D3 regulates Ca~V~3.2 channels through a non-canonical, arrestin-dependent pathway. The D3 plays therefore a unique role in the regulation of pyramidal cell excitability ([@B44]). The D3 receptor function has received attention because it could be a discriminant of the clinical effect of different antipsychotics ([@B70]) and because of the potential to address SCZ negative symptoms. In fact, D3 are associated to a cortical circuit important for all the different SCZ symptoms. The D3 controlled PFCx projections to hippocampus are interesting in this sense ([@B155]). The recent paper from Meier et al. shows the effect of a preferential D3 partial agonist Cariprazine on gamma oscillations in hippocampal slides further supporting the general assumption that gamma waves could predict psychosis and *in vitro* NMDA hypofunction, and that D3 functional reduction can stabilize the alterations of the signal caused by NMDA hypofunction ([@B130]). Treatment response to antipsychotics may be predicted looking at the effect on hippocampal- cortical connections and again these changes could be in part D3 related ([@B78]; [@B17]). The observed hippocampal alterations in some SCZ patients (psychotic) also support the presence of hippocampal immaturity at least in a subgroup of SCZ patients ([@B4]; [@B31]). There is therefore a renewed interest for the hippocampal models in SCZ, because it is possible to study developmental changes which are closer to those observed in man and because it is easier to obtain NMDA receptor hypofunction ([@B4]). In a mouse model of postnatal NMDA hypofunction (NR1a KO) the effect seems to be selectively associated with PV+ interneurons (in cortex and hippocampus among other areas). In this animal model both cortical hypo- and striatal hyperdopaminergic phenotypes can be observed ([@B139]). The reason(s) behind these extensive dopaminergic changes across areas are still not fully understood, but SCZ genetic data related to ancillary proteins for the NMDA receptor function also support this hypothesis. Very recent work has also given renewed attention to circuit(s) involving PFCx areas like DL or the orbitofrontal (and cerebellum) in relation to some aspects of negative symptoms in SCZ ([@B209]; [@B24]). It is possibly too early to include a conclusive map of DR expression in within these pathways. The DISC-1 developmental mouse model could however help to analyze these circuit(s), considering the main impairment observed in sociability measures ([@B189]). The PV+ interneurons can also be a starting point to address the network in terms of developmental changes. Recent DISC-1 studies report a reduction of spontaneous inhibitory transmission onto L2/3 PV+ interneurons in medial PFCx and a decreased feed forward inhibition onto L2/3 pyramidal neurons ([@B53]).

Striatal Circuits Alteration(s) in SCZ and DR {#s3_2}
---------------------------------------------

The main role of the striatum is the integration of cortical and thalamic glutamatergic projections ([@B91]; [@B128]). The striatum is at the center of a DA-sensitive basal ganglia circuit associated with psychosis, SCZ related motor dysfunctions and reward deficits. A summary of all the direct and indirect evidences of striatal DA alterations in SCZ was recently published ([@B129]). All data confirm the presence of presynaptic DA sensitization and elevated DA synthesis and release capacity ([@B26]; [@B217]). Higher striatal DA synthesis and higher DA release correlated with worsening of psychotic symptoms in SCZ patients and were also supported by neuromelanin observation ([@B218]). Excess striatal DA in SCZ is not related to changes in DA innervation ([@B220]). There have been extensive efforts to describe the neuroanatomy of striatum, and the cellular distribution of DR ([@B183]; [@B44]). Substantia nigra DA projections mainly reach the dorsal striatum ([@B200]) while ventral tegmental area (VTA) projections from the mesencephalon reach the ventral striatum (nAcc). Striatal neurons that receive DA inputs are mainly GABAergic medium spiny neurons (MSN). MSN neurons are the recipients of both DA and glutamatergic (from PFCx and thalamus) projections, they represent therefore a core neuronal element for both DA and NMDA hypothesis in SCZ. The MSN projecting to the internal segment of globus pallidus/nigra pars reticulata express D1 receptors, while those projecting to the external segment of globus pallidus are essentially expressing the D2 receptors. The two types of neurons are finely intermingled across the whole striatum ([@B163]). There is also a not so small population of MSN that express both D1 and D2 receptors. They are usually described as enkephalin receptor positive neurons, they express specifically the subunit GluA3 of the AMPA receptor and project broadly to nuclei containing DA neurons cell bodies, to the nAcc and the ento-peduncular nucleus among others ([@B151]). The cross talk of interneurons at this level is a main filter on the cortical input. Clearly, different DR contribute to the final effect, depending on receptor distribution across different types of interneurons ([@B29]). For example the D1 activity in MSN is inhibited by the cholinergic tonus (M4 mediated) ([@B138]). In SCZ increased spine density have been observed in dorsal striatum MSN. Converging evidences suggest a critical role of the dopaminergic system in adapting synaptic plasticity of glutamatergic inputs (synaptic spines). Early in development, the DA system has fundamental roles in forebrain differentiation and circuit formation ([@B25]), but DA tone also has clear effects on glutamatergic spine density at adult stage. It is however not clear how SCZ specific NMDA alterations could impact on the system. The recent and seminal work of the group of Prof. Groc, using single molecule-based imaging shows that NMDA antibodies present in some SCZ patients with psychotic symptoms are specifically changing the surface dynamics and nanoscale organization of synaptic NMDA and its anchoring partner the EphrinB2 receptor in synaptic spines in hippocampal neurons, ultimately preventing LTP potentiation ([@B96]; [@B97]). As expected this causes a small reduction of the D1 surface expression in the same cellular system ([@B75]). The associated intracellular DA signaling effects however could be more deeply modified because of this lack of NMDA/D1 interaction. It would be equally important to study these NMDA-antibody related changes in the context of the striatal circuits in particular on MSN D1 mediated signal and during development. The D1 receptor in dorsal striatum has been also involved in the sensorimotor gating alterations observed in SCZ but these mechanisms needs to be verified in man and with selective agents given the main differences in anatomical connectivity ([@B3]).

Striatal D2/D3 Receptors and SCZ {#s3_3}
--------------------------------

There are main differences in the DA input across the different striatal regions. This is particularly true for the D2 receptor function across dorsal striatum and nAcc. Increased DA D2 sensitivity in the nAcc is related to differences in coupling to Go vs. Gi ([@B126]). The striatal D2 related control on reward is a key aspect of the effects of antipsychotics. Psychotic symptoms have been in fact linked to salience changes in the reward system circuit and blocking D2 controls psychotic symptoms including a normalization on reward disturbances ([@B82]). A direct relationship between D2 receptor blockade, normalization of reward processing and symptom improvement was recently further supported by a small study in antipsychotic-naive first-episode SCZ patients ([@B225]). Cognitive flexibility (reversal learning) is another aspect of D1/D2 related deficits that is linked to DA striatal functional regional differences ([@B172]). The cellular basis of the role of striatal D1 vs. D2 in reward and learning have been further clarified by the work of Iino et al., 2020, showing in rodents the presence of a D2 controlled spine plasticity in MSN, that can be reversed with a D2 antagonist ([@B93]).

D2 antagonism is still recognized as a main stay of SCZ therapy and the D2 receptor is considered to be directly or indirectly responsible for the efficacy of the majority of typical and atypical antipsychotics. This is coherent with the general observation of a main role of DA control of cortico-striatal synchronization of D2-MSN neurons (via D2-GPRIN AKT) ([@B100]). The tetra complex A2A-D2 receptors (plus AC5) is really central to multiple effects of both adenosine and DR ligands in the striatal region ([@B64]; [@B19]). mGlu5 receptor can be also included in a complex interaction with D2-A2A in GABAergic neuronal terminals providing a multiple way to increase GABA release ([@B22]; [@B171]). It is becoming therefore apparent that D2 receptor function is heterogeneous and possibly strictly dependent on the neuronal type expressing the receptor in different cortical and sub-cortical regions. Considering the role of D2 receptor in the control of emotional, cognitive and sensory functions alterations in SCZ it is therefore important to revisit the molecular aspects of this receptor and possibly even the pharmacology of the different antipsychotics ([@B160]). For instance the D1/D2 complex (possibly) present in some MSN exhibits the remarkable property of a coupling to a Gq- PLC mediated increase in intracellular calcium release and CAMKII phosphorylation ([@B151]). This complex may represent an interesting new pharmacological target in SCZ. The D2S receptor is involved whenever SCZ treatment resistance is discussed or phenomena of presynaptic D2 receptor supra-sensitivity induced by antipsychotics ([@B5]).

Motivational deficits in SCZ are most likely associated with cortico-striatal circuits involving the VTA, and the ventral striatum ([@B1]; [@B107]). Clinical observation keep suggesting some involvement of ventral striatum in the control of motivation, emotions and social behavior as relevant for negative symptoms in SCZ with regular debates on the matter ([@B61]; [@B186]; [@B210]). Interestingly, D3 receptor expression is enriched in midbrain ventral striatum (including nAcc) ([@B182]) where the receptor is present on pre- and postsynaptic locations and can also work in cooperation with the receptor D1 (in MSN - AKT signal) ([@B35]; [@B77]). The D3 receptor has been linked to control of DA firing in VTA, emotion and reward control in animal models ([@B191]), but the lack of selective D3 ligands has so far hampered specific research on the subject ([@B46]). Cholinergic interneurons in the ventral striatum, particularly those in the insula major of Calleja are highly enriched in D3 receptor, making these cells extremely sensitive to DA from VTA projections. Also in this case a D1/D3 complex is probably present. In this region as well as in cerebellum or other extra-striatal circuits, the D3 receptor has been linked to thermoregulation and sleep/wakefulness, which are potentially relevant for the control of some aspects of SCZ ([@B122]). Calleja islands are also a site related to adult neurogenesis in ventral striatum across species: these neurons are D3, Erb4 and neuroregulin1 positive.

Section 3. DR Ligands and SCZ Therapies. The New Wave of Ligands With Potential Relevance for Therapy or Brain Imaging {#s4}
======================================================================================================================

The discovery that DA effective drugs for treating SCZ is redeemable to the elegant work of Carlsson and Lindqvist in the early 60's and to the identification, a decade later, of the antipsychotics/DA receptor. Atypical antipsychotics developed in the 70's and 80's, included serotoninergic complementary mechanisms, as observed with clozapine, the prototypical atypical antipsychotic, to improve treatment compliance ([@B8]). Historical perspectives on SCZ drugs generally highlight the DA receptor D~2~ antagonism as main mechanism of action ([@B124]), but the pharmacology of antipsychotics is much more complex and requires a specific discussion on DR selectivity and serotonin receptor poly-pharmacology ([@B30]; [@B8]; [@B135]; [@B28]). Important discoveries were made in the DA field during the past decade, in particular in relation to the pharmacology of DR ligands. DR heterodimers have been described in different brain regions and used to explain the complex biological effects associated with DR activation ([@B23]). Exciting data from crystallographic studies have supported a wave of drug discovery projects looking for new antipsychotics ([@B39]; [@B214]; [@B215]). DR signaling versatility is further magnified by context dependent dissecting signatures or "bias" ([@B203]) extending the potential for optimized pharmacological interventions. It is possible for instance to separate β-arrestin mediated signals using biased D1 agonists ([@B201]; [@B74]). Several recent contributions are available on this matter ([@B206]). The potential therapeutic applications of biased D2 ligands to new SCZ therapies, has fuelled new interest on D2S vs. D2L or cAMP independent intracellular pathways, looking for agents with less motor side effects. D2 β-arrestin-biased ligands are now available ([@B147]) and they may provide some pharmacological advantages, at least on the basis of the results in preclinical models ([@B203]). These agents are not per se D2 selective since they also interact with the D3 receptor and might require the presence of an heteromeric complex with the receptor A2a for the final effect. There is therefore a need for a different look at DR ligands pharmacology *in vitro*. We should possibly reconsider aspects like receptor internalization or intracellular recycling also for the main active metabolites or when comparing antagonists and partial agonists ([@B52]). See [**Table 2 Supplementary Material**](#SM1){ref-type="supplementary-material"} for chemical series of DR ligands and representative compounds described in section 3.

DR Ligand Receptor Interactions {#s4_1}
-------------------------------

The most interesting finding in the field of DR is certainly the crystal structure of D2, D3. and D4 receptors and how this was used to identify new series or new mechanisms of ligand receptor interaction. Homology models are also extremely helpful for D1 and D5 with some main limitation for specific domains with reduced identity ([@B28]). The DA binding site is contained in a membrane pocket formed by the TM3/5/6/7 with similarities across biogenic amines GPCRs. Molecular docking studies for the D1 receptor were able to demonstrate the presence of allosteric sites that were further targeted to obtain highly selective positive allosteric modulators with high potency, weak agonist properties and able to increase DA response (cAMP) ([@B27]). The mode of interaction of biased agonists is different since they fail to trigger D1 receptor desensitization *in vitro*. The current model supposes a docking in within the DA site, but with differences in interactions with TM3/5 and extracellular loop 2 ([@B74]). The rapid advance of the pharmacology of D1 receptors bringing new drugs to the clinic is a clear demonstration of the therapeutic impact of research on DR-ligand interactions ([@B80]). For D2/D3 biased ligands the drug design is complicated by the needed poly-pharmacology vs. 5-HT1A or 5-HT2A receptors which contribute to the clinical efficacy and also is intrinsic to some pharmacophore ([@B123]). The ligands cocrystallized in the different D2/D3 studies are haloperidol, risperidone, nemonapride and eticlopride, non-selective but potent antagonists ([@B60]). Thus no main difference was expected. In reality the results show differences in D2 inactive conformation that suggest different receptor inactive states ([@B112]). In addition the agonist binding pocket in the D2 allows an extension that has been used to study D2 \> D3 and D4 selectivity (with agonist ligands) and to determine the possibility to obtain biased agonists for D2 ([@B60]). The re-assessment of the D2 interaction profile of different classes of D2 antagonists is also on the way ([@B244]). The case of D3 is complementing this picture given the variety of new ligands currently available. Subtype-selective compounds have been sought for more than two decades with difficulties achieving sufficient selectivity and central exposure. Clinical PET data have recently provided encouraging results with cariprazine and F17464 ([@B182]). More recent D3 over D2 new ligands have been obtained exploiting the presence of a secondary allosteric D3 pocket to generate bitopic ligands with long molecular bridges. This strategy has allowed a powerful expansion in chemical possibilities even while maintaining the capacity to generate agents with biased activities ([@B169]; [@B19]). The concept of bitopic ligands is associated with the presence of two separated regions of the receptor with different vectors relevant for the affinity and the allosteric pocket interaction (usually driving D3/D2 selectivity considerations). Shorter D3 ligands will necessarily reside instead only in within the orthosteric pocket. Some interesting caged ligands for the D2/D3 orthosteric pocket could possibly help further pharmacological studies on this subject in native systems ([@B68]). There is a second interesting aspect in the pharmacology of D3 bitopic ligands. It has allowed to show the presence of an alternative mechanism of D3 receptor internalization independent of β-arrestin and used by group II GPCR ([@B228]). Considering the excess D2 homodimers detected in schizophrenia ([@B211]), the effects of DA antagonists on these entities has been specifically explored using bivalent ligands ([@B156]; [@B224]). A molecular model of the homodimer has been also generated for D2 to provide docking information relative to bivalent ligands with different pharmacological properties (for example orthosteric and allosteric agents) ([@B99]). Other DR heterodimers were also considered as selective targets for this type of ligands ([@B33]), mainly because the differential expression of these dimeric receptor entities may allow a more precise approach to specific brain structures and pathways ([@B47]; [@B65]).

DR-Ligand Interaction Dynamics and Efficacy Studies {#s4_2}
---------------------------------------------------

There are classic aspects of receptor pharmacology like constitutive activity or equilibria across receptor conformations which are quite difficult to address with DR, in particular when considering heterocomplexes. It should be however possible to better distinguish antagonists from partial agonists and systematically discuss on and off rates vs. affinity measures when presenting new DR ligands. Species specific differences are also seldom acknowledged. This systematic pharmacological work is required to make sense of the complex *in vivo* pharmacology of DR ligands (in particular D2/D3) also for antipsychotics already on the market. The case of D2 and D3 receptors is indeed quite interesting in this sense because of the complexity of the structure/activity database required to select new candidates and validate efficacy in comparison to reference antipsychotics. Several groups have generated a variety of synthetic ligands concurring to build similar molecular models including dynamic aspects of DR receptor activation over time. In recombinant systems at least, we witness some amazing activity switches between agonist and "antagonist" properties across different series that require further dynamic considerations ([@B193]). Destabilization of D3 inactive state(s) and flexibility of the ligands are among the elements that the most recent model available is proposing ([@B63]). Molecular recognition steps, changes in hydration of the ligand binding pocket and ligand dependent receptor configuration changes are also important considerations for D2 and D3 in particular when docking flexible ligands and establishing comparisons ([@B145]). Native system pharmacology studies are due to confirm the relevance of the observed *in vitro* differences. It would be indeed interesting to obtain a database of consistent functional information for all the ligands generated to further advance in the direction of new therapeutics. A re-evaluation of known DR ligands in the clinic on the basis of the latest available molecular model would be useful to help DR drug developers to build a more integrated view on the efforts, the tools and the information available and needed to move forward.

Conclusion {#s5}
==========

This article reviews current knowledge on DR subtypes in SCZ, anatomical distribution, and new pharmacological tools that can help dissect out subtype-specific functions. The aspects of DR research described hereby are strictly related to SCZ or risk genes associated with it. What appears is that the current molecular understanding of Glutamate NMDA - DA interactions in SCZ has improved, but it is still insufficient in particular in brain areas like the ventral striatum and in relation to negative symptoms. A better understanding of the circuit(s) will possibly further reduce boundaries between cognitive and negative SCZ symptoms domains ([@B167]). The DA - NMDA research is also bringing the neurodevelopmental aspects of the SCZ disease to the core of current efforts and hopefully this will improve our understanding of SCZ disease onset and the relevance of DR research in SCZ animal models. It is therefore essential to integrate all the most recent DR findings and further discuss the NMDA Glutamate -- DA dysregulation hypothesis for SCZ with a focus on the key interactors between the two systems ([@B103]; [@B154]). This may also help drug discovery to address the complexity of DR heterocomplexes in native systems using multiple intracellular markers and benefiting from the available more selective DR tools.
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